Olivier Delattre, MD, PhD, Honored with 2023 AACR-St. Baldrick’s Foundation Award for Outstanding Achievement in Pediatric Cancer Research
March 29, 2023
For Immediate Release
For media inquiries, please contact Julia Gunther at firstname.lastname@example.org or 770-403-7690. For a photo of Delattre, click here. Visit our newsroom.
PHILADELPHIA – The American Association for Cancer Research (AACR) will award Olivier Delattre, MD, PhD, with the 2023 AACR-St. Baldrick’s Foundation Award for Outstanding Achievement in Pediatric Cancer Research during the AACR Annual Meeting 2023, April 14-19 at the Orange County Convention Center in Orlando, Florida.
Delattre is the director of the SIREDO Oncology Center and the research unit director of the Cancer, Heterogeneity, Instability and Plasticity (CHIP) unit at Inserm/Institut Curie. He is being recognized for a series of seminal genetic insights into the etiology of pediatric solid tumors that have had substantial clinical implications.
The AACR and the St. Baldrick’s Foundation established the AACR-St. Baldrick’s Foundation Award for Outstanding Achievement in Pediatric Cancer in 2019 to bring attention to major pediatric cancer research discoveries and to honor individuals who has significantly contributed to any area of pediatric cancer research, resulting in the fundamental improvement of the understanding and/or treatment of pediatric cancer.
Delattre is internationally heralded for having transformed the field of pediatric cancer research by opening new avenues for pediatric cancer screening, while improving the precision of molecular diagnostics. He was the first to report the molecular characterization of the EWS-FLI1 chromosomal translocation in Ewing sarcoma, which is now central to the accurate diagnosis of that cancer. He has also been instrumental in identifying genetic alterations in other childhood cancers, including the BCOR-CCNB3 translocation in Ewing-like sarcoma and ALK mutations in neuroblastoma and other EWS-translocation-positive sarcomas. He was one of the first to demonstrate the existence of mutations within chromatin remodeling complexes in cancer, which are now known to occur in approximately 20% of human cancers. Delattre’s work has been crucial to identifying major cancer predisposition genes for neurofibromatosis type 2, neuroblastoma, and a rhabdoid tumor predisposition syndrome, generating new insights into pediatric cancer susceptibility.
Delattre has been a leader in developing genetically engineered mouse models for neuroblastoma and rhabdoid tumors. These models have been used to evaluate candidate drug targets, assess therapeutic efficacy, and investigate drug resistance mechanisms. He has explored the oncogenic plasticity of pediatric cancers, furthering our understanding of the development of pediatric solid tumors. More recently, his work has focused on the identification of tumor-specific neogenes driven by chimeric transcription factors in sarcoma, work that has the potential to establish innovative avenues for the development of new therapeutic approaches for pediatric cancer.
Delattre has been an AACR member since 2015. He joined the AACR’s Pediatric Cancer Working Group (PCWG) in 2013 and has served on the AACR-PCWG Steering Committee since 2020. He has served as a member of the AACR-Aflac Inc. Career Development Award for Pediatric Cancer Research Scientific Review Committee (2016-2018); member of the AACR-St. Baldrick’s Foundation Award for Outstanding Achievement in Pediatric Cancer Research Committee (2019-2020); and member of the AACR Pediatric Cancer Research Grants Scientific Review Committee (2019-2021).
Delattre’s work has been recognized with many awards and honors, such as the Inserm Grand Prix (2022), the Jeremy Jass Prize for Research Excellence in Pathology (2019), The Fondation ARC Léopold Griffuel Award (2016), the CTOS Herman Suit Special Award Lecture (2014), the Charles Oberling Award (2009), the EUROCANCER Award (2007), the Award of the Académie Nationale de Médecine (2000), the Gaston Rousseau Award of Académie des Sciences (1996), the Olga Sain Award of Comité de Paris of the Ligue Nationale Contre le Cancer (1995), the Fondation pour la Recherche Médicale Rose Lamarca Award of Clinical Investigation (1995), the EURE Award of the Ligue Nationale Contre le Cancer (1993), and the Jacques Sylvain Bourdin Award of Comité de l’Essonne of the Ligue Nationale Contre le Cancer (1993). He was elected as a member of the Academia Europea (2012) and the European Molecular Biology Organization (2011).
Delattre received his medical degree from Pierre and Marie Curie University and earned his PhD in molecular biology from Paris Diderot University in France.
Delattre’s award lecture, titled “Ewing sarcoma, a paradigm for cell reprogramming in cancer,” will be held on Tuesday, April 18 at 5 p.m. ET at the Orange County Convention Center.
Follow the meeting on Twitter: #AACR23
Follow us: Cancer Research Catalyst; Twitter; and Facebook
For AACR information, visit Fast Facts.
About the American Association for Cancer Research
Founded in 1907, the American Association for Cancer Research (AACR) is the world’s first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 54,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and patient advocates residing in 130 countries and territories around the world. Presently, 32% of members live outside the United States and 22% of AACR’s international members are located in countries with emerging economies. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, diagnosis, and treatment of cancer by annually convening more than 30 conferences and educational workshops, the largest of which is the AACR Annual Meeting. In addition, the AACR publishes 10 prestigious, peer-reviewed scientific journals and a magazine for cancer survivors, patients, and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration, and scientific oversight of team science and individual investigator grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and other policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit www.AACR.org.
About St. Baldrick’s Foundation
Every 2 minutes, a child somewhere in the world is diagnosed with cancer. In the U.S., 1 in 5 will not survive. The St. Baldrick’s Foundation, the largest charity funder of childhood cancer research grants, is on a mission to Conquer Kids’ Cancer by supporting the most promising research to find cures and better treatments for all childhood cancers. When you give to St. Baldrick’s, you don’t just give to one hospital – you support virtually every institution with the expertise to treat kids with cancer across the U.S. St. Baldrick’s ensures that children fighting cancer now — and those diagnosed in the future — will have access to the most cutting-edge treatment, by supporting every stage of research, from new ideas in the lab to the training of the next generation of researchers, to lifesaving clinical trials. Visit StBaldricks.org and help #ConquerKidsCancer.
Recent Press Releases
- May 25, 2023 St. Baldrick’s Foundation Welcomes Julia Glade Bender, M.D., of Memorial Sloan Kettering to its Board of Directors
- April 6, 2023 The Catch a Million Pokémon Charity Event Announces Community Partners and Giant Incentives
- April 3, 2023 Sport Clips Haircuts furthers its commitment to fund childhood cancer research through first in-store St. Baldrick’s fundraiser
- March 29, 2023 Olivier Delattre, MD, PhD, Honored with 2023 AACR-St. Baldrick’s Foundation Award for Outstanding Achievement in Pediatric Cancer Research